Coherus Oncology, Inc. (CHRS) Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Coherus Oncology, Inc. NASDAQ:CHRS Healthcare · Biotechnology
Mkt Cap $128.25M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 3
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Coherus Oncology reported interim TREGCHECK data showing tagmokitug plus toripalimab and chemo achieved a 75% confirmed ORR in front-line esophageal squamous cell carcinoma, rising to 89% after the data cutoff, versus a 44-59% standard-of-care benchmark for PD-L1 positive patients.
Second-line ESCC showed durable benefit with the 700 mg dose, including 5.5-month median PFS versus a ~3.4-month chemo benchmark, and activity was seen across five indications in over 120 patients with no new safety signals.
The company plans to expand enrollment in both ESCC cohorts and is advancing tagmokitug in additional combinations, including a planned T-cell engager study in mCRPC.
• 4d ago AI analysis › Press Release
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology announced it will participate in two upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, and the Jefferies Global Healthcare Conference in London on November 16, 2026.
Presentations will be webcast with replays available for 30 days, and one-on-one management meetings can be requested through bank representatives.
No financial results, guidance, or pipeline updates were included in the release.
• 5d ago AI analysis › Press Release
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Coherus Oncology will release its third quarter 2026 financial results on Monday, November 9, 2026, with a conference call and webcast at 5:00 p.m. Eastern.
This is a scheduling announcement only; no results or business updates were disclosed.
Investors can pre-register for the call and access replays via the company's investor relations website.
• 6d ago AI analysis › Press Release
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Coherus Oncology announced it will disclose interim clinical data for tagmokitug, its cytolytic anti-CCR8 antibody, on October 28, 2026, with a management webcast from 4:30 to 6:00 p.m. ET.
The data cover tagmokitug in combination with LOQTORZI (toripalimab) across multiple solid tumors; tagmokitug is in Phase 1b/2a studies in head and neck, colorectal, gastric and esophageal cancers.
Key opinion leaders have been invited to the webcast, which will be archived on the company's investor site. No data are disclosed in this release; the October 28 event is the catalyst to watch.
• 18d ago AI analysis › Press Release ⚠ 2
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Coherus Oncology initiated a process to market and sell its legacy biosimilar assets, retaining Oppenheimer & Co. as financial advisor to solicit bids.
Net proceeds from any sale or licensing will be distributed to shareholders via contingent value rights (CVRs) previously declared on August 17, 2026, with a September 30 record date and October 7 distribution date.
CVR holders may receive little or no payment if no transaction is consummated, and shareholders whose shares are rehypothecated or loaned out as of the record date may not receive CVRs at all.
• 1mo ago AI analysis › Press Release
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology announced that management will participate in three upcoming investor conferences: the Baird 2026 Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference.
Live webcasts of the presentations will be accessible via the Coherus investor website, with replays available for 30 days following the events.
Investors interested in scheduling one-on-one meetings with company management during the conferences are advised to contact their respective bank representatives.
• 2mo ago AI analysis › Press Release ⚠ 3
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology declared a special dividend of Contingent Value Rights (CVRs), entitling stockholders of record as of September 30, 2026, to a pro rata share of net proceeds from the future sale of its legacy biosimilar assets.
The transaction marks the completion of the company's strategic transformation into a fully integrated oncology business, divesting assets including patents, royalties, and cell lines to focus on its proprietary pipeline.
The CVRs are non-transferable and will expire on October 7, 2028, if the Legacy BioSim Assets are not monetized, though the company has retained an investment bank to immediately commence the sale process.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
Coherus reported Q2 2026 total net revenue of $14.3 million, up 39% from the prior year, driven by a 37% increase in LOQTORZI revenue to $13.6 million. The company narrowed its net loss to $0.22 per share, compared to a loss of $0.39 per share in the same period last year.
Commercial momentum for LOQTORZI continued with the highest number of new patient starts since launch, while the pipeline advanced with the completion of enrollment for the Phase 2 casdozokitug study in first-line unresectable hepatocellular carcinoma.
Cash, cash equivalents, and marketable securities totaled $105.3 million as of June 30, 2026, down from $172.1 million at year-end 2025, as the company invested in clinical trials and operations.
• 2mo ago AI analysis › Press Release
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Coherus Oncology scheduled the release of its second quarter 2026 financial results for Wednesday, August 5, 2026.
Management will host a conference call and webcast at 5:00 p.m. Eastern Daylight Time on that date to discuss the results and provide a business update.
A replay of the webcast will be available on the company's investor relations website following the live event.
• 3mo ago AI analysis › Press Release
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology and Zumutor Biologics announced a clinical collaboration to evaluate ZM008 in combination with LOQTORZI in a Phase 1 trial targeting various solid tumors including colorectal, head and neck, and NSCLC.
Under the supply agreement, Zumutor will sponsor the trial while Coherus provides LOQTORZI, allowing Coherus to gather clinical data and expand indications cost-efficiently.
The study (NCT06451497) will enroll up to 45 patients to evaluate safety, tolerability, and recommended dosing for the novel NK checkpoint and PD-1 inhibitor combination.
• 4mo ago AI analysis › Press Release ● Major
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com • 5mo ago Press Release
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Coherus Oncology announced that it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026.
Management will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the results and provide a general business update.
A webcast replay will be available on the Coherus investor relations website following the conclusion of the live event.
• 5mo ago AI analysis › 
